Lundbeck closes RNA deal worth USD 109m with US biotech firm

Danish pharmaceutical firm Lundbeck enters a strategic collaboration with US biotech group Rgenta in order to find small molecules targeting RNA and develop new treatments for neurological diseases. To start with, the Danish company pays DKK 63m, and in time, it might end up paying DKK 628m in milestone payments.
Lundbeck Vice President Klaus Bæk Simonsen | Photo: Lundbeck / PR
Lundbeck Vice President Klaus Bæk Simonsen | Photo: Lundbeck / PR
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN & DANIEL FRANK CHRISTENSEN

New treatments for rare brain diseases in a potentially very lucrative market.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading